Company Overview and News

 
Ambuja Cements moves up in Dow Jones Sustainability Index

2018-09-18 thehindubusinessline
Our Bureau Ambuja Cements, part of the global conglomerate LafargeHolcim and one of the leading cement manufacturing companies in India, has moved up two notches to rank fifth globally in the Dow Jones Sustainability Index for construction materials.
500425 AMBUY AMBUJACEM

 
Ambuja Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500425 AMBUY AMBUJACEM

 
Realty, cement stocks rise after reports of lifting of ban on construction

2018-09-06 thehindubusinessline
Realty and cement stocks rose on reports the apex court had lifted construction ban in Maharashtra and Uttarakhand. The Nifty Realty index was up as much as 1.8 per cent.
500425 AMBUY UCLQY UCLQF 532538 532832 AMBUJACEM IBREALEST ULTRACEMCO

 
Ambuja Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500425 AMBUY AMBUJACEM

 
Ambuja Cements (₹238.7): Buy

2018-08-22 premium.thehindubusinessline
On Tuesday, the stock jumped 4 per cent accompanied with extraordinary volume, decisively breaching a key resistance at ₹233. The stock has been in a short-term uptrend since recording a 52-week low at ₹189 on July 17. While trending up, the stock had conclusively breached its 21-as well as 50-day moving averages and a significant resistance at ₹210 in late July. After a corrective decline, the stock appears to have resumed its short-term uptrend.
500425 AMBUY AMBUJACEM

 
S&P BSE Sensex Next 50 in the limelight

2018-08-21 thehindubusinessline
While the Sensex closed near flat at 38,285 on Tuesday, the S&P BSE Sensex Next 50 advanced 229 points or 0.67 per cent to close at 34,634.7. UPL, Ambuja Cements, Glenmark and Cummins advanced in the range of 4-6.7 per cent. The advance/decline was biased towards advance with 30 stocks gaining against 20 declining. The S&P BSE Sensex Next 50 measures the performance of the next 50 largest and liquid stocks after the constituents of S&P BSE Sensex 50 in the S&P BSE LargeMidCap.
500425 AMBUY AMBUJACEM

 
Government allows conditional import of petcoke

2018-08-18 freepressjournal.in
Mumbai : The government on Friday allowed import of petcoke for use as feedstock in some industries, sending shares of cement manufacturers higher.
500425 AMBUY UCLQY 500387 UCLQF 532538 AMBUJACEM SHREECEM ULTRACEMCO

 
Ambuja Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500425 AMBUY AMBUJACEM

 
Ambuja Cements Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500425 AMBUY AMBUJACEM

 
ACC and Ambuja Cements result review: Healthy volume growth and operational performance

2018-07-27 moneycontrol
ACC and Ambuja Cements, two of India's biggest cement companies controlled by global cement giant Lafarge Holcim, reported a decent set of earnings in the second quarter of 2018 on the back of healthy volume growth. The operating profit margins of both these companies improved on a quarter-on-quarter (QoQ) basis on the back of modest growth in realisations and operating efficiencies.
532532 500425 AMBUY JIPKY JPASSOCIAT AMBUJACEM

 
An evening walk down Dalal Street | Sensex, Nifty manage to end at record closing highs; PSU banks surge

2018-07-26 moneycontrol
A record high opening, clinching key milestones and turning volatile ahead of expiry of derivatives and yet manage to end at a record highs—the market had it all in a day’s trade. The 50-share index managed to scale a fresh record high of 11,185.85, surpassing the previous levels of 11,171 that was recorded earlier this year. There was some last hour volatility and weakness ahead of F&O expiry, but PSU banks’ strength ensured that it managed to clock fresh record highs on both indices.
YESBANK 500425 IBN 532648 YYBKY AMBUJACEM CNRYY ICICIBANK 532483 AMBUY 532174 CANBK SBAZ

 
Ambuja Cements gains 7% on strong Q2 nos; CLSA maintains buy with target Rs 300

2018-07-26 moneycontrol
Shares of Ambuja Cements gained 7.6 percent intraday Thursday as company posted strong numbers in the quarter ended June 2018.
500425 AMBUY 500387 AMBUJACEM SHREECEM

 
Q1 results: Ambuja Cements earnings beat estimates, but stock remains a laggard

2018-07-26 livemint
Ambuja Cements Ltd’s volumes surged 5.28% year-on-year to 6.37 million tonnes (mt) in the June quarter. In comparison, volumes of peers UltraTech Cement Ltd and ACC Ltd’s stood at 16.8mt and 7.24mt, respectively, in the same quarter. On a stand-alone basis, Ambuja Cements’ net profit rose 27% year-on-year to ₹ 499.27 crore. This figure includes a dividend of ₹ 141 crore from material subsidiary ACC.
500425 AMBUY UCLQY UCLQF 532538 AMBUJACEM ULTRACEMCO

 
Ambuja Cements posts 27% rise in second-quarter profit, beats expectations

2018-07-25 moneycontrol
India's Ambuja Cements Ltd posted a 27 percent growth in second-quarter profit on Wednesday, beating market estimates, helped by higher cement sales and lower expenses.
HCMLY 500425 HCMLF AMBUY AMBUJACEM

 
Ambuja Cements Limited - Investor Presentation

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500425 AMBUY AMBUJACEM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...